Business
BATM develops molecular diagnostics test for TB
BATM develops molecular diagnostics test for TB.
About this update from Batm Advanced Communications Ltd.
[{"type":"text","content":"\n \n \n \n RNS Number : 7188T\n BATM Advanced Communications Ld\n 29 March 2021\n \n \n \n \n LEI: \n 213800FLQUB9J289RU66\n \n \n 29 March 2021\n \n \n \n \n \n BATM Advanced Communications Limited\n \n \n (\"BATM\" or \"the Group\")\n \n \n \n \n \n BATM develops molecular diagnostics test for tuberculosis\n \n \n Clinical trials of BATM's new method for the rapid and comprehensive diagnosis of TB will be fully funded by the Stop TB Partnership\n \n \n \n \n \n BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (\"TB\"). The testing and validation phase, which is expected to commence in the second half of this year, will be fully funded under a programme of the Stop TB Partnership, an international alliance comprising a wide range of governmental and non-governmental organisations. \n \n \n \n \n \n The new method combines a one-step PCR test, developed by the Group's Adaltis subsidiary, with testing on the NATlab instrument using the new isothermal RCA process developed by the Group's Ador Diagnostics associate company. The \n PCR test diagnoses if someone is infected with TB and, if they test positive, the NATlab system is used to identify the strain of TB and its resistance to antibiotics (including \n rifampicin, isoniazid and quinolones). This process, which tests the same sample in both phases, is expected to produce results in approximately two hours, compared with several days for the current commonly used methods that often rely on incubation to determine antibiotic resistance after a patient has been diagnosed as infected with TB. \n \n \n \n \n \n The Group presented this new method, which is being developed with the cooperation of a leading university in Italy, to the Stop TB Partnership at the end of 2019 and, following ongoing discussions, has now received the organisation's backing. The testing and validation of the solution will take place at the University of Heidelberg and will be fully funded under a programme of the Stop TB Partnership. \n \n \n \n \n \n Following the testing and validation phase, which is expected to begin in the second half of this year, the Group anticipates commenci...